Two-step retrograde closed stenting: a novel method for treating canalicular lacerations in Chinese patients

Purpose

To evaluate the efficacy of two-step retrograde closed stenting for treating canalicular laceration.

Methods

Forty-eight consecutive canalicular laceration cases (48 eyes) were randomised and divided into two groups: a one-step group and a two-step group. In the two-step group (23 cases), the first step was performed in the outpatient department and included identifying the medial cut end of the canaliculus and probing under a slit-lamp microscope, followed by a retrograde canalicular stenting assisted by a memory titanium stylet. The second step was canalicular anastomosis, which was performed in the operating room. In the one-step group (25 cases), all of the surgical procedures were performed when preoperative preparations were simultaneously available.

Results

The time elapsed from the doctor visit to the treatment was 4.3±2.4 h in the two-step group and 18.8±6.3 h in the one-step group (P<0.01). The canalicular medial cut ends were found in all cases, but 8.6±3.5 min was needed in the two-step group, and 51.4±24.2 min was needed in the one-step group (P<0.01). The numerical rating scale for pain during surgery was 1.8±1.2 in the two-step group and 5.4±2.2 in the one-step group (P<0.01). One case (2.63%) in the two-step group and nine cases (36%) in the one-step group required other assisted methods to locate the medial cut end (P=0.007). Twenty-one cases (91.3%) in the two-step group and 20 cases (80%) in the one-step group achieved patent lacrimal drainage systems during a 12-month follow-up (P=0.528).

Conclusions

The two-step canalicular anastomosis method allows an early search for the medial cut end of the canaliculus and improves the chances of finding it; it is also a quicker, less invasive method for treating canalicular lacerations.     

利福平对兔脂肪干细胞增殖、成骨及黏附支架的影响

目的探讨利福平（rifampicin,RFP）对兔脂肪干细胞（rabbitadipose-derivedstemcells,rADSCs）增殖、成骨及黏附支架的影响,为后期RFP缓释系统与rADSCs的复合奠定实验基础。方法分离培养rADSCs,检测细胞周期及表面抗原CD44,成骨、成脂诱导后分别行茜素红及油红O染色。用利福平生长液干预rADSCs,按浓度分为0、10、20及30μg／ml4组,分别绘制细胞生长曲线、检测细胞凋亡率及碱性磷酸酶（alkalinephosphatase,ALP）含量。制备同种异体脱钙骨支架,并复合各组rADSCs,计算细胞黏附率,扫描电子显微镜观察复合情况。结果rADSCs呈长梭形生长,G0／G1期占78．3％±4．2％,表面抗原CD44阳性表达。成骨诱导后茜素红染色及成脂诱导后油红O染色均为阳性。生长曲线示30μg／ml组第4-11天增殖能力较其他3组弱（P〈0．01）,细胞凋亡示30μg／ml组凋亡率高于其他3组（P〈0．01）,ALP检测示成骨诱导后第14天30μg／ml组ALP含量较其他3组少（P〈0．01）,细胞黏附率示30μg／ml组较其他3组低（P〈0．01）。扫描电镜观察30μg／ml组黏附的细胞数量少,形态松散。结论不影响rADSCs增殖、成骨及黏附支架的RFP临界浓度约为20μg／ml。     

大学生性别角色类型与安全感的关系

目的探讨大学生性别角色类型与安全感的关系。方法采用《大学生性别角色量表》和《安全感量表》对选取的461名大学生进行调查。结果1在大学生4种性别角色类型中,男性化、女性化、双性化、未分化类型所占的比例分别为24.7%、23.2%、25.6%、26.5%;2不同性别角色类型大学生安全感水平由高到低依次是双性化、男性化、女性化和未分化类型者;双性化个体安全感水平显著高于其他3种类型个体(F=12.600,P0.01);3大学生性别角色男、女正性量表得分与安全感得分呈显著正相关(r=0.37和0.15,P0.01)。结论不同性别角色类型个体的安全感存在显著差异。     

Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis

Background:Gastric cancer (GC) is a strong cause of global cancer mortality. Nucleotide excision repair (NER) can modulate platinum-based chemotherapeutic efficacy by removing drug-produced DNA damage. Some studies have found a link between excision repair cross complementation group 1 (ERCC1) rs2298881, one gene in NER pathway, and response to chemotherapy. However, the results have been disputed.Methods:We conducted a meta-analysis to reevaluate the association between polymorphisms of NER gene (ERCC1 rs2298881) and the clinical outcomes in gastric cancer patients receiving platinum-based chemotherapy. Searching PubMed, Web of Science, EMBASE, Google Scholar, and China National Knowledge Infrastructure, 2 independent searchers found all pertinent literatures up to May 1, 2021. We enrolled studies according to consistent selection criteria, extracted and vitrified data. Crude odds ratios (ORs) and hazard ratios (HRs) with 95% confidence interval (CI) were applied to evaluate the effect of ERCC1 rs2298881 on patients treated by platinum-based chemotherapy.Results:By the data gathered from 6 independent studies, 1940 cases diagnosed with gastric cancer and treated with chemotherapy were included, containing 1208 Good-Responders and 732 Poor-Responders. With a comprehensive meta-analysis, we found that the patients with ERCC1 rs2298881A allele had a worse response to chemotherapy than those who with rs2298881C allele under allelic model (A vs C), with the pooled OR of 0.780 (95% CI: 0.611–0.996, P = .046). And our analysis indicated that AA genotype was associated with unfavorable overall survival (HR = 1.540, 95% CI = 1.106–2.144, P = .011) compared with CC genotype.Conclusions:ERCC1 rs2298881 is suggested as a marker of clinical outcome in gastric cancer patients treated by platinum-based chemotherapy.     

High-performance liquid chromatographic determination and pharmacokinetic study of vitexin-2'-O-rhamnoside in rat plasma after intravenous administration

A simple and specific high-performance liquid chromatographic (HPLC) method was developed for the pharmacokinetic study of vitexin-2'-O-rhamnoside (VOR) in rat after intravenous administration. The plasma samples were deproteinized with methanol after addition of internal standard (i.s.) hesperidin. HPLC analysis was performed on a Diamonsil ODS C18 analytical column, using acetonitrile-0.3% formic acid (20:80, v/v) as the mobile phase with UV detection at 270 nm. The standard curve was linear over the range of 0.1070-21.41 microg/mL in rat plasma. The average extraction recovery of VOR was 97.9+/-3.1%, and the relative standard deviations (R.S.D.s) of the intra- and inter-day precisions were no more than 7.4 and 8.5%, respectively. The lower limit of quantification (LLOQ) was 0.1070 microg/mL. The AUC of VOR was proportional to the dose after intravenous administration of 15, 30, 60 and 120 mg/kg body weight, and the elimination half-life (t1/2beta), systemic clearance (Cl) and apparent volume of distribution (Vc) were not significantly different among the four doses, and all the results indicated that the pharmacokinetics of VOR in rat obeyed first-order kinetics.     

Design and synthesis of pentahydroxylhexylamino acids and their effect on lead decorporation

A series of enantiopure pentahydroxylhexylamino acids 4a-t were synthesized via an improved one-pot-three-step procedure. Their potential as antagonists for lead intoxication was investigated both in vitro and in vivo. Lead decorporation assays in vivo confirmed that after treatment with 4a-t, the levels of lead in treated mice were significantly reduced in the liver, kidney, bone, and brain compared to those in the control group. In addition, the lead levels in feces and urine were significantly higher after treatment with 4a-t than those of the control group. In particular, the lead decorporation potency of compounds 4b, 4i, 4j, and 4s were comparable or better than that of dl-penicillamine. Furthermore, new chelating agents did not affect the levels of endogenous essential metals. The stability constants of the formed lead complexes of 4a-t were determined by potentiometric titration. It seems that the therapeutic efficiency of the lead chelating agents depends on factors that affect the stability constants of the formed lead complexes. The membrane permeability of representative compounds was evaluated in a Caco-2 cell monolayer. A good correlation between in vitro results and in vivo lead decorporation capacity of the chelating agents was observed. Some of these new pentahydroxylhexylamino acids (4b, 4i, 4j, and 4s) may be developed as effective lead chelating agents.     

HPLC determination and pharmacokinetic study of homoeriodictyol-7-O-beta-D-glucopyranoside in rat plasma and tissues

Homoeriodictyol-7-O-beta-D-glucopyranoside (HEDT-Glu) was isolated from Viscum coloratum and identified by MS, 1H- and 13C-NMR. A HPLC method was developed for determination of HEDT-Glu in rat plasma and tissues. All biological samples were pretreated by protein precipitation with acetone. Vanillin was selected as internal standard. The mobile phase consisted of methanol-water-glacial acetic acid (45 : 55 : 0.5, v/v/v). Good linearity were observed over the concentration ranges of 0.1-200.0 microg.ml(-1) in rat plasma and 0.05-5.0 microg.ml(-1) in tissues. Both intra- and inter-day precisions of HEDT-Glu, expressed as the relative standard deviation, were less than 13.1%. Accuracy, expressed as the relative error, ranged from -0.8 to 5.4% in plasma and from -5.6 to 9.4% in tissues. The mean extraction recovery of HEDT-Glu was above 73.17% in biological samples. The described assay method was successfully applied to the pre-clinical pharmacokinetic study of HEDT-Glu. After intravenous administration of HEDT-Glu to rat, AUC and CL(tot) were 16.04+/-3.19 microg.h.ml(-1) and 0.85+/-0.17 l.kg(-1).h(-1), respectively. T(1/2,alpha) and t(1/2,beta) were 0.06+/-0.01 h and 1.27+/-0.31 h, respectively. HEDT-Glu was cleared from the blood and mainly distributed to the liver and small intestine.     

新生儿不规则抗体检测的临床意义

目的：检测新生儿红细胞血型不规则抗体,探讨不规则抗体与新生儿溶血病的关系。方法：对521例新生儿溶血病待确诊患儿通过微柱凝胶卡进行直接抗人球白试验、游离抗体测定、放散试验,不规则抗筛选阳性标本进一步进行不规则抗体鉴定,同时进行不规则抗筛选阳性患儿母亲血型鉴定及不规则抗体筛选、鉴定。结果：检测出抗-D 4例,抗-E 3例,抗-c1,抗-M 1例。结论：应重视孕妇IgG类红细胞血型不规则抗体筛查;根据不规则抗体的特性,可为患儿选择无相应抗原的血液进行综合治疗和换血。